Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-06-08T05:18:51.833Z Has data issue: false hasContentIssue false

20 - Relapsed acute myeloid leukemia

from Part III - Evaluation and treatment

Published online by Cambridge University Press:  01 July 2010

By
Ursula Creutzig
Edited by
Ching-Hon Pui
Ursula Creutzig
Affiliation:
Professor, Pediatric Hematology/Oncology, University Children's Hospital Münster, Münster, Germany
Ching-Hon Pui
Affiliation:
St. Jude Children's Research Hospital, Memphis
Get access

Summary

Introduction

About 80% to 90% of children with newly diagnosed acute myeloid leukemia (AML) achieve complete remission (CR) with intensive induction chemotherapy. However, 10% to 20% of patients do not achieve remission due to early death by hemorrhage, leukostasis, infection or resistant disease (primary refractory AML), and even after achieving remission, 30% to 50% of patients still relapse. Primary refractory AML and relapsed AML have a poor prognosis, with an overall survival of less than 25%. For patients in first relapse, the prognosis mainly depends on the time of relapse. If it is early, defined as within 1 to 1.5 years after initial diagnosis, the second CR rate is about 50% and overall survival 10% or less. If the time of relapse is late, defined as later than 1.5 years after diagnosis, the second CR rate is 80% to 90% with an overall survival of up to 40%. Multiple-relapsed AML has an even worse prognosis. The management of refractory or relapsed AML is quite difficult. Several treatment schedules have been studied recently, and progress seems feasible with the use of new drugs and novel drug combinations followed by hematopoietic stem cell transplantation (HSCT).

Definition

Relapse is defined as the reappearance of leukemic cells at any site in the body. Most relapses in AML occur during treatment, mostly during the first year after diagnosis. Relapses after 2 years are rarely seen (Fig. 20.1).

Type
Chapter
Information
Childhood Leukemias , pp. 540 - 547
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Creutzig, U., Ritter, J., Zimmermann, M., et al.Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia, 2001; 15: 348–54.CrossRefGoogle ScholarPubMed
Stevens, R. F., Hann, I. M., Wheatley, K., & Gray, R. G., on behalf of the MRC Childhood Leukaemia Working Party. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol, 1998; 101: 130–40.CrossRefGoogle ScholarPubMed
Stahnke, K., Boos, J., Bender-Gotze, C., et al.Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia. 1998; 12: 1534–8.CrossRefGoogle ScholarPubMed
Reinhardt, D., Hempel, G., Fleischhack, G., et al.[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Klin Pädiatr, 2002; 214: 188–94.CrossRefGoogle Scholar
Webb, D. K., Wheatley, K., Harrison, G., , Stevens R. F., & Hann, I. M.Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia, 1999; 13: 25–31.CrossRefGoogle ScholarPubMed
Kozu, T., Miyoshi, H., Shimizu, K., et al.Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood, 1993; 82: 1270–6.Google Scholar
Jaeger, U., Kusec, R., & Haas, O. A.Detection of AML1/ETO rearrangements in acute myeloid leukemia with a translocation t(8;21). Haematol Blood Transfus, 1995; 37: 475–7.Google Scholar
Tobal, K., Newton, J., Macheta, M., et al.Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood, 2000; 95: 815–19.Google Scholar
Wattjes, M. P., Krauter, J., Nagel, S., et al.Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia, 2000; 14: 329–35.CrossRefGoogle Scholar
Miller, W. H., Kakizuka, A., & Frankel, S. R.Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 1992; 89: 2694–8.CrossRefGoogle ScholarPubMed
Diverio, D., Rossi, V., Avvisati, G., et al.Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial. GIMEMA-AIEOP Multicenter “AIDA” Trial. Blood, 1998; 92: 784–9.Google ScholarPubMed
Tobal, K. & Liu, Y. J.RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia, 1998; 12: 1349–54.CrossRefGoogle ScholarPubMed
Leith, C. P., Kopecky, K. J., Chen, I. M., et al.Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 1999; 94: 1086–9.Google ScholarPubMed
List, A. F.The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia, 1996; 10(Suppl. 1): S36–8.Google ScholarPubMed
Leith, C.Multidrug resistance in leukemia. Curr Opin Hematol, 1998; 5: 287–91.CrossRefGoogle ScholarPubMed
Schaich, M., Ritter, M., Illmer, T., et al.Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol, 2001; 112: 300–7.CrossRefGoogle ScholarPubMed
List, A. F., Spier, C. S., Grogan, T. M., et al.Overexpression of the major vault transporter protein lung–resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 1996; 87: 2464–9.Google ScholarPubMed
Sonneveld, P.Multidrug resistance in acute myeloid leukaemia. Baillieres Clin Haematol, 1996; 9: 185–203.CrossRefGoogle ScholarPubMed
Vossebeld, P. J. & Sonneveld, P.Reversal of multidrug resistance in hematological malignancies. Blood Rev, 1999; 13: 67–78.CrossRefGoogle ScholarPubMed
Dahl, G. V., Lacayo, N. J., Brophy, N., et al.Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol, 2000; 18: 1867–75.CrossRefGoogle ScholarPubMed
Liu Yin, J. A., Wheatley, K., Rees, J. K. H., & Burnett, A. K.Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Brit. J. Haematol, 2001; 113: 713–26.CrossRefGoogle ScholarPubMed
Smeets, M., Raymakers, R., Muus, P., et al.Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance. Leukemia, 2001; 15: 80–8.CrossRefGoogle ScholarPubMed
Fleischhack, G., Hasan, C., Graf, N., Mann, G., & , Bode U.IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol, 1998; 102: 647–55.CrossRefGoogle ScholarPubMed
Miller, L. P., Pyesmany, A. F., Wolff, L. J., et al.Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group. Cancer, 1991; 67: 2235–40.Google ScholarPubMed
Ozkaynak, M. F., Avramis, V. I., Carcich, S., & Ortega, J. A.Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. Med Pediatr Oncol, 1998; 31: 475–82.3.0.CO;2-7>CrossRefGoogle ScholarPubMed
Santana, V. M., Mirro, J. Jr., Harwood, F. C., et al.A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol, 1991; 9: 416–22.CrossRefGoogle ScholarPubMed
Steuber, C. P., Krischer, J., Holbrook, T., et al.Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol, 1996; 14: 1521–5.CrossRefGoogle ScholarPubMed
Webb, D. K.Management of relapsed acute myeloid leukaemia. Br J Haematol, 1999; 106: 851–9.CrossRefGoogle ScholarPubMed
Whitlock, J. A., Wells, R. J., Hord, J. D., et al.High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia. Leukemia, 1997; 11: 185–9.CrossRefGoogle ScholarPubMed
Jeha, S., Gandhi, V., Chan, K. W., et al.Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 2004; 103: 784–9.CrossRefGoogle ScholarPubMed
Gandhi, V., Estey, E., Keating, M. J., Chucrallah, A., & Plunkett, W.Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood, 1996; 87: 256–64.Google ScholarPubMed
Szmigielska, A., Góra-Tybor, J., & Robak, T.Influence of 2-chlorodeoxyadenosine alone and in combiantion with cytosine arabinoside on murine leukemias L1210 and P388. Cancer J, 1996; 9: 319–22.Google Scholar
Robak, T., Wrzesien-Kus, A., Lech-Maranda, E., Kowal, M., & Dmoszynska, A.Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma, 2000; 39: 121–9.CrossRefGoogle ScholarPubMed
Visani, G., Tosi, P., Zinzani, P. P., et al.FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ‘poor risk’ acute myeloid leukemias. Leukemia, 1994; 8: 1842–6.Google ScholarPubMed
Estey, E., Thall, P., Andreeff, M., et al.Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol, 1994; 12: 671–8.CrossRefGoogle ScholarPubMed
Plunkett, W., Huang, P., Searcy, C. E., & Gandhi, V.Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol, 1996; 23(Suppl. 10): 3–15.Google ScholarPubMed
Lech-Maranda, E., Korycka, A., & Robak, T.Influence of gemcitabine (2′,2′-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro. Eur J Haematol, 2000; 65: 317–21.CrossRefGoogle ScholarPubMed
Maranda, E., Szmigielska, A., & Robak, T.Additive action of gemcitabine (2′,2′-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388. Cancer Invest, 1999; 17: 95–101.Google ScholarPubMed
Estey, E. H.New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids. Leukemia, 1998; 12(Suppl. 1): S13–15.Google ScholarPubMed
Cortes, J., , Estey E., Beran, M., et al.Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma, 2000; 36: 479–84.CrossRefGoogle ScholarPubMed
Abella, E. & Ravindranath, Y.Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation. Curr Oncol Rep, 2000; 2: 529–38.CrossRefGoogle ScholarPubMed
Hermann, J., Schiller, I., Fuchs, D., et al.Autologous bone marrow transplantation in first complete remission as intensification therapy in children with high risk AML – results of the Pediatric Cooperative AML Trial 1987–1992 in East Germany. Haematol Blood Transfus, 1998; 39: 803–9.Google Scholar
Clift, R. A., Buckner, C. D., Appelbaum, F. R., et al.Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol, 1992; 10: 1723–9.CrossRefGoogle ScholarPubMed
Ringden, O., Labopin, M., Frassoni, F., et al.Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 1999; 24: 389–96.CrossRefGoogle ScholarPubMed
Amadori, S., Testi, A. M., Aricó, M., et al.Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol, 1993; 11: 1046–54.CrossRefGoogle ScholarPubMed
Locatelli, F., Pession, A., Bonetti, F., et al.Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia, 1994; 8: 844–9.Google ScholarPubMed
Gale, R. P. & Horowitz, M. M.Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant, 1990; 6(Suppl. 1): 94–7.Google ScholarPubMed
Powles, R., Singhal, S., Treleaven, J., et al.Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood, 1998; 91: 3481–6.Google ScholarPubMed
Elmaagacli, A. H., Beelen, D. W., Trenn, G., et al.Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant, 1999; 23: 771–7.CrossRefGoogle ScholarPubMed
Singhal, S., Powles, R., Kulkarni, S., et al.Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk Lymphoma, 1999; 32: 505–12.CrossRefGoogle ScholarPubMed
De la Rubia, J., Sanz, G. F., Martin, G., et al.Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. Bone Marrow Transplant, 1996; 18: 1167–73.Google ScholarPubMed
Guidez, F., Ivins, S., Zhu, J., et al.Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood, 1998; 91: 2634–42.Google ScholarPubMed
Douer, D., Estey, E., Santillana, S., et al.Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood, 2001; 97: 73–80.CrossRefGoogle ScholarPubMed
Niu, C., Yan, H., Yu, T., et al.Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999; 94: 3315–24.Google ScholarPubMed
Shen, Z. X., Chen, G. Q., Ni, J. H., et al.Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997; 89: 3354–60.Google ScholarPubMed
Soignet, S. L., Maslak, P., Wang, Z. G., et al.Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 1998; 339: 1341–8.CrossRefGoogle ScholarPubMed
Buchdunger, E., Zimmermann, J., Mett, H., et al.Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 1996; 56: 100–4.Google ScholarPubMed
Scappini, B., Onida, F., Kantarjian, H. M., et al.Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res, 2001; 7: 3884–93.Google ScholarPubMed
Reuter, C. W., Morgan, M. A., & Bergmann, L.Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies ?Blood, 2000; 96: 1655–69.Google ScholarPubMed
Willman, C. L.Targeted AML therapy: new biologic paradigms and therapeutic opportunities. Leukemia, 2001; 15: 690–4.CrossRefGoogle ScholarPubMed
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., et al.Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 1999; 93: 3678–84.Google ScholarPubMed
Sievers, E. L., Larson, R. A., Stadtmauer, E. A.et al.Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin Oncol, 2001; 19: 3244–54.CrossRefGoogle ScholarPubMed
Sato, Y., Asada, Y., Hara, S., et al.Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology, 1999; 34: 66–70.CrossRefGoogle ScholarPubMed
Matthews, D. C., Appelbaum, F. R., Eary, J. F., et al.Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood, 1999; 94: 1237–47.Google ScholarPubMed
Claxton, D. & Choudhury, A.Potential for therapy with AML-derived dendritic cells. Leukemia, 2001; 15: 668–9.CrossRefGoogle ScholarPubMed
Aguayo, A., Kantarjian, H., Manshouri, T., et al.Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 2000; 96: 2240–5.Google ScholarPubMed
Padro, T., Ruiz, S., Bieker, R., et al.Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 2000; 95: 2637–44.Google ScholarPubMed
Schuch, G., Oliveira-Ferrer, L., Loges, S., et al.Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia, 2005, 19: 1312–17.CrossRefGoogle ScholarPubMed
Roboz, G. J., Dias, S., Lam, G., et al.Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 2000; 96: 1525–30.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×